Home
/ Mylan
/ Financials & Metrics

Mylan (MYL) stock price, revenue, and financials

Mylan market cap is $8.6 b, and annual revenue was $11.50 b in FY 2019

View Company

-1.59 (-9.09%)

$8.6 B

MYL Mkt cap, 19-Jan-2021

$3 B

Mylan Revenue Q3, 2020

Mylan Gross profit (Q3, 2020)1.2 B

Mylan Gross profit margin (Q3, 2020), %39%

Mylan Net income (Q3, 2020)185.7 M

Mylan EBIT (Q3, 2020)351.4 M

Mylan Cash, 30-Sept-2020664.5 M

Mylan EV20.3 B

Mylan Revenue

Mylan revenue was $11.50 b in FY, 2019 which is a 0.6% year over year increase from the previous period.

Embed Graph

Mylan Revenue Breakdown

Embed Graph

Mylan revenue breakdown by business segment: 16.0% from Central Nervous System & Anesthesia, 14.5% from Infectious Disease, 15.9% from Respiratory & Allergy, 7.8% from Cardiovascular, 10.0% from Gastroenterology, 7.3% from Diabetes & Metabolism, 6.3% from Women’s Health, 9.2% from Oncology and 13.0% from Other

Mylan revenue breakdown by geographic segment: 27.9% from Rest of World, 36.6% from North America and 35.5% from Europe

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Revenue	11.9b	11.4b	11.5b
Revenue growth, %		(4%)	1%
Cost of goods sold	7.1b	7.4b	7.6b
Gross profit	4.8b	4.0b	3.9b
Gross profit Margin, %	40%	35%	34%
R&D expense	783.3m	704.5m	639.9m
General and administrative expense	2.6b	2.4b	2.6b
Operating expense total	3.3b	3.1b	3.2b
EBIT	1.4b	905.6m	715.5m
EBIT margin, %	12%	8%	6%
Interest expense	534.6m	542.3m	517.3m
Pre tax profit	903.0m	298.4m	154.4m
Income tax expense	207.0m	(54.1m)	137.6m
Net Income	696.0m	352.5m	16.8m
EPS	1.3	0.7	0.0

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Revenue	2.7b	2.8b	2.9b	2.5b	2.9b	3.0b	2.6b	2.7b	3.0b
Cost of goods sold	1.7b	1.8b	1.8b	1.7b	1.9b	1.9b	1.7b	1.7b	1.8b
Gross profit	984.3m	962.5m	1.0b	805.2m	932.6m	1.1b	906.1m	1.0b	1.2b
Gross profit Margin, %	37%	34%	36%	32%	33%	36%	35%	38%	39%
R&D expense	204.9m	206.7m	144.1m	172.6m	147.6m	167.9m	114.2m	156.3m	129.8m
General and administrative expense	607.5m	623.3m	577.3m	607.9m	668.6m	632.7m	605.4m	719.4m	658.4m
Operating expense total	828.6m	783.6m	701.0m	781.2m	837.1m	748.7m	721.4m	891.5m	807.1m
EBIT	155.7m	178.9m	338.2m	24.0m	95.5m	323.7m	184.7m	134.2m	351.4m
EBIT margin, %	6%	6%	12%	1%	3%	11%	7%	5%	12%
Interest expense	131.7m	139.2m	136.2m	131.2m	131.2m	128.9m	119.9m	116.2m	117.3m
Pre tax profit	10.5m	18.7m	192.2m	(114.5m)	(52.1m)	185.8m	30.7m	20.0m	241.6m
Income tax expense	(76.6m)	(18.8m)	15.5m	(89.5m)	116.4m	(4.0m)	9.9m	(19.4m)	55.9m
Net Income	87.1m	37.5m	176.7m	(25.0m)	(168.5m)	189.8m	20.8m	39.4m	185.7m
EPS	(0.2)	0.1	0.3	0.0	(0.3)	0.4	0.0	0.1	0.4

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Cash	292.1m	388.1m	475.6m
Accounts Receivable	3.6b	2.9b	3.1b
Prepaid Expenses	766.1m	518.4m	552.0m
Inventories	2.5b	2.6b	2.7b
Current Assets	7.2b	6.4b	6.8b
PP&E	2.3b	2.2b	2.1b
Goodwill	10.2b	9.7b	9.6b
Total Assets	35.8b	32.7b	31.3b
Accounts Payable	1.5b	1.6b	1.5b
Short-term debt	1.9b	701.7m	1.5b
Current Liabilities	6.4b	4.6b	5.6b
Long-term debt	12.9b	13.2b	11.2b
Total Debt	14.7b	13.9b	12.7b
Total Liabilities	22.5b	20.6b	19.4b
Common Stock	6.0m	6.0m	6.1m
Additional Paid-in Capital	8.6b	8.6b	8.6b
Retained Earnings	5.6b	6.0b	6.0b
Total Equity	13.3b	12.2b	11.9b
Debt to Equity Ratio	1.1 x	1.1 x	1.1 x
Debt to Assets Ratio	0.4 x	0.4 x	0.4 x
Financial Leverage	2.7 x	2.7 x	2.6 x

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Cash	367.4m	330.2m	449.2m	229.8m	211.5m	358.9m	572.4m	323.6m	664.5m
Accounts Receivable	3.0b	2.8b	2.9b	2.8b	2.7b	2.9b	2.8b	2.8b	3.0b
Prepaid Expenses	728.0m	588.4m	583.2m	545.2m	573.9m	574.7m	613.9m	602.1m	684.1m
Inventories	2.6b	2.6b	2.6b	2.7b	2.8b	2.8b	2.6b	2.8b	3.0b
Current Assets	6.8b	6.3b	6.5b	6.3b	6.3b	6.6b	6.6b	6.5b	7.3b
PP&E	2.3b	2.2b	2.1b	2.2b	2.1b	2.1b	4.1b	2.0b	2.1b
Goodwill	10.3b	9.9b	9.8b	9.6b	9.7b	9.4b	9.3b	9.5b	9.8b
Total Assets	35.2b	33.3b	33.5b	31.9b	31.8b	31.1b	30.1b	30.2b	31.2b
Accounts Payable	1.4b	1.3b	1.4b	1.3b	1.5b	1.5b	1.3b	1.3b	1.4b
Short-term debt	2.7b	1.4b	1.2b	703.9m	750.6m	605.3m	1.5b	3.2b	3.2b
Current Liabilities	6.4b	4.9b	5.2b	4.2b	4.6b	4.6b	5.2b	7.0b	7.3b
Long-term debt	12.5b	13.3b	13.3b	13.1b	12.6b	12.5b	11.2b	9.0b	9.1b
Total Debt	15.1b	14.7b	14.5b	13.8b	13.3b	13.1b	12.7b	12.2b	12.3b
Total Liabilities	22.0b	21.1b	21.4b	20.0b	19.9b	19.6b	18.9b	18.4b	18.7b
Common Stock	6.0m	6.0m	6.0m	6.0m	6.1m	6.1m	6.1m	6.1m	6.1m
Additional Paid-in Capital	8.6b	8.6b	8.6b	8.6b	8.6b	8.6b	8.7b	8.7b	8.7b
Retained Earnings	5.8b	5.8b	6.0b	6.0b	5.8b	6.0b	6.1b	6.1b	6.3b
Total Equity	13.2b	12.2b	12.1b	11.9b	11.9b	11.5b	11.3b	11.7b	12.5b
Debt to Equity Ratio	1.1 x	1.2 x	1.2 x	1.2 x	1.1 x	1.1 x	1.1 x	1 x	1 x
Debt to Assets Ratio	0.4 x	0.4 x	0.4 x	0.4 x	0.4 x	0.4 x	0.4 x	0.4 x	0.4 x
Financial Leverage	2.7 x	2.7 x	2.8 x	2.7 x	2.7 x	2.7 x	2.7 x	2.6 x	2.5 x

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Net Income	696.0m	352.5m	16.8m
Depreciation and Amortization	1.8b	2.1b	2.0b
Accounts Receivable	(162.2m)	340.1m	(20.0m)
Inventories	(129.5m)	(547.6m)	(512.9m)
Accounts Payable	14.4m	220.3m	(96.3m)
Cash From Operating Activities	2.1b	2.3b	1.8b
Purchases of PP&E	(275.9m)	(252.1m)	(213.2m)
Cash From Investing Activities	(905.4m)	(1.2b)	(525.4m)
Short-term Borrowings	(2.9m)	(44.4m)	(1.8m)
Long-term Borrowings	(2.2b)	(3.2b)	(1.1b)
Cash From Financing Activities	(1.9b)	(1.1b)	(1.2b)
Net Change in Cash	(706.7m)	19.4m	101.8m
Interest Paid	474.0m	460.8m	470.6m
Income Taxes Paid	285.7m	228.6m	278.6m

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Net Income	87.1m	124.6m	301.3m	(25.0m)	(193.5m)	(3.7m)	20.8m	60.2m	245.9m
Depreciation and Amortization	498.5m	1.0b	1.5b	500.5m	1.0b	1.5b	415.0m	830.7m	1.3b
Accounts Receivable	370.2m	479.0m	262.2m	62.8m	198.9m	(20.7m)	73.6m	122.6m	(27.3m)
Inventories	(157.6m)	(280.7m)	(425.5m)	(183.0m)	(326.8m)	(477.6m)	(131.8m)	(275.8m)	(532.4m)
Accounts Payable	(92.8m)	(130.6m)	(14.1m)	(277.5m)	(71.6m)	(83.2m)	(201.0m)	(234.5m)	(99.7m)
Cash From Operating Activities	621.8m	1.1b	1.7b	(39.7m)	629.2m	1.1b	291.1m	670.6m	1.2b
Purchases of PP&E	(30.7m)	(75.9m)	(137.4m)	(53.1m)	(97.2m)	(139.6m)	(43.4m)	(87.9m)	(126.1m)
Cash From Investing Activities	(428.9m)	(732.7m)	(1.0b)	(75.6m)	(234.0m)	(410.9m)	(145.6m)	(220.1m)	(278.8m)
Short-term Borrowings	309.1m	179.0m	(45.9m)	(1.5m)	24.3m	(1.9m)			300.0k
Long-term Borrowings	(498.0m)	(2.6b)	(2.6b)	(200.0k)	(555.5m)	(657.1m)	(33.0m)	(589.0m)	(588.9m)
Cash From Financing Activities	(121.4m)	(289.9m)	(514.7m)	(40.1m)	(571.9m)	(704.6m)	(24.8m)	(609.1m)	(754.8m)
Net Change in Cash	75.2m	14.3m	133.2m	(158.4m)	(176.6m)	(14.9m)	96.8m	(166.4m)	176.0m

USD	FY, 2017
EV/EBIT	25.8 x
EV/CFO	18 x
Revenue/Employee	340.2k
Debt/Equity	1.1 x
Debt/Assets	0.4 x
Financial Leverage	2.7 x
P/E Ratio	32.5

	FY, 2017	FY, 2018	FY, 2019
Products	7.50 k	7.50 k	7.50 k
Countries	165	165	165
Products (Cardiovascular)		1.15 k	1.15 k
Products (Dermatology)		500	500
Products (Gastroenterology)		700	700
Products (Infectious Disease)		1.10 k	1.10 k
Products (Respiratory)		600	600
Products (Women's Health)		650	650
Products (Anesthesia)		1.90 k	1.90 k
Products (Diabetes & Metabolism)		450	450
Patents Issued		4.50 k	5 k
Products (Immunology)		80	80
Products (Oncology)		450	450
Products in Pipeline (Anesthesia)		550	400
Products in Pipeline (Cardiovascular Disease)		320	300
Products in Pipeline (Dermatology)		60	60
Products in Pipeline (Diabetes & Metabolism)		300	250
Products in Pipeline (Gastroenterology)		150	100
Products in Pipeline (Immunology)		100	75
Products in Pipeline (Infectious Disease)		900	800
Products in Pipeline (Oncology)		550	500
Products in Pipeline (Respiratory & Allergy)		150	150
Products in Pipeline (Women’s Health)		150	150
Research and Development Centers		12	12

	FY, 2019
Water Used (Rainwater)	1 k cubic meters
Water Used (Other)	3 k cubic meters
Water Used (On-Site Borewell)	100 k cubic meters
Water Used (Municipal)	3.16 m cubic meters
Water Recycled	475 k cubic meters
Water Discharged	1.57 m cubic meters
Water Consumed	3.26 m cubic meters
Waste Recycled, percent	74%
Waste Generated	69 k tonnes
Total Recordable Incident Rate	0.67
Total Greenhouse Gas Emissions	670 k tonnes
Total Energy Used	611 GWh
Number of Fatalities	0
Nonhazardous Waste Generated	24 k tonnes
Lost Time Incident Rate	0.41
Hazardous Waste Generated	45 k tonnes
Greenhouse Gas Emissions Intensity	58 tonnes per million USD revenue
Greenhouse Gas Emissions (Scope 2)	354 k tonnes
Greenhouse Gas Emissions (Scope 1)	316 k tonnes
Energy Used from Renewable Energy Sources	90 GWh
Energy Used from Non-renewable Energy Sources	521 GWh
Energy Intensity Ratio	0.05 GWh per million USD revenue
Dart Rate	0.47

Gender

	FY, 2018	FY, 2017
Female, percent	29.8 %	28.3 %
Male, percent	70.2 %	71.7 %

Source: ungc-production.s3.us-west-2.amazonaws.com, ungc-production.s3.us-west-2.amazonaws.com

Job Roles

	FY, 2018	FY, 2017
Female (Management), percent	8.9 %	8.7 %
Male (Board), percent	22.2 %	21.3 %
Female (Board), percent	11.1 %	12 %
Sales and Marketing, percent	7 %	6.6 %
Operations, percent	19 %	19.3 %
Male (Management), percent	24.4 %	24.7 %
Other	7.3 %	7.4 %

Source: ungc-production.s3.us-west-2.amazonaws.com, ungc-production.s3.us-west-2.amazonaws.com

Culture & Values

3.3

Work/Life Balance

3.3

Senior Management

3.1

Salary & Benefits

3.8

Career Opportunities

3.5

Source

View Mylan profile

Competitors

Amgen

Healthcare - Public

BioMarin Pharmaceutical

Mylan (MYL) stock price, revenue, and financials

$15.855

$8.6 B

$3 B

Mylan Revenue

Mylan Revenue Breakdown

Mylan Income Statement

Annual

Revenue

Revenue growth, %

Cost of goods sold

Gross profit

Gross profit Margin, %

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Interest expense

Pre tax profit

Income tax expense

Net Income

EPS

Quarterly

Revenue

Cost of goods sold

Gross profit

Gross profit Margin, %

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Interest expense

Pre tax profit

Income tax expense

Net Income

EPS

Mylan Balance Sheet

Annual

Cash

Accounts Receivable

Prepaid Expenses

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Short-term debt

Current Liabilities

Long-term debt

Total Debt

Total Liabilities

Common Stock

Additional Paid-in Capital

Retained Earnings

Total Equity

Debt to Equity Ratio

Debt to Assets Ratio

Financial Leverage

Quarterly

Cash

Accounts Receivable

Prepaid Expenses

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Short-term debt

Current Liabilities

Long-term debt

Total Debt

Total Liabilities

Common Stock

Additional Paid-in Capital

Retained Earnings

Total Equity